The 36-month beta value for TELO is at -0.39. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TELO is 17.25M, and currently, shorts hold a 13.30% of that float. The average trading volume for TELO on June 20, 2025 was 199.55K shares.
TELO) stock’s latest price update
The stock of Telomir Pharmaceuticals Inc (NASDAQ: TELO) has decreased by -5.38 when compared to last closing price of 1.86. Despite this, the company has experienced a -10.66% fall in its stock price over the last five trading sessions. accessnewswire.com reported 2025-06-18 that Study used cell lines obtained from the Progeria Research Foundation to evaluate Telomir-1’s effects on key drivers of accelerated aging MIAMI, FLORIDA / ACCESS Newswire / June 18, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a preclinical-stage biotechnology company focused on reversing biological aging and age-related diseases, today announced compelling new preclinical data showing that its lead candidate, Telomir-1, prevented cellular aging in human progeria cell lines obtained from the Progeria Research Foundation. Progeria, or Hutchinson-Gilford Progeria Syndrome (HGPS), is an ultra-rare pediatric disorder caused by a mutation in the LMNA gene.
TELO’s Market Performance
Telomir Pharmaceuticals Inc (TELO) has seen a -10.66% fall in stock performance for the week, with a -30.71% decline in the past month and a -59.54% plunge in the past quarter. The volatility ratio for the week is 4.10%, and the volatility levels for the past 30 days are at 4.87% for TELO. The simple moving average for the last 20 days is -13.38% for TELO stock, with a simple moving average of -57.24% for the last 200 days.
Analysts’ Opinion of TELO
Many brokerage firms have already submitted their reports for TELO stocks, with Rodman & Renshaw repeating the rating for TELO by listing it as a “Buy.” The predicted price for TELO in the upcoming period, according to Rodman & Renshaw is $15 based on the research report published on February 21, 2025 of the current year 2025.
TELO Trading at -25.06% from the 50-Day Moving Average
After a stumble in the market that brought TELO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.05% of loss for the given period.
Stock Fundamentals for TELO
The total capital return value is set at 78.05. Equity return is now at value -876.77, with -626.79 for asset returns.
Currently, EBITDA for the company is -12.19 million with net debt to EBITDA at 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.75.
Conclusion
In conclusion, Telomir Pharmaceuticals Inc (TELO) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
